1. Argani P, Martignoni G, Mehra R, Yu W. TFE3-rearranged renal cell carcinomas. In: Moch H, editors. Urinary and Male Genital Tumours. 5th ed. Lyon, France: World Health Organization International Agency for Research on Cancer. 2022. pp. 72–73.

2. Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(7):1392–1424. 10.1038/s41379-021-00779-w

3. Akgul M, Williamson SR, Ertoy D, Argani P, Gupta S, Caliò A, et al. Diagnostic approach in TFE3-rearranged renal cell carcinoma: A multi-institutional international survey. J Clin Pathol. 2021;74(5):291–299. 10.1136/jclinpath-2020-207372

4. Caliò A, Marletta S, Brunelli M, Pedron S, Portillo SC, Segala D, et al. TFE3 and TFEB-rearranged renal cell carcinomas: An immunohistochemical panel to differentiate from common renal cell neoplasms. Virchows Arch. 2022;481:877–891. 10.1007/s00428-022-03380-x

5. Sharain RF, Gown AM, Greipp PT and Folpe AL. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: A comparative, 2-laboratory study. Hum Pathol. 2019;87:65–74. 10.1016/j.humpath.2019.02.008

6. Gomolcˇáková J, Brezinová B, Dubovan P, Jurišová S, Rejlekova K, Chovanec M, et al. Targeted therapy in Xp11 translocation renal cell carcinoma. Klin Onkol. 2021;34(2):137–140. 10.48095/ccko2021137

7. Murakami S, Nagawa K, Inui T, Yamamoto A, Suzuki M, Koga F, et al. Case reports of TFE3-rearranged renal cell carcinoma: FDG-PET uptake might help diagnosis. J Kidney Cancer VHL. 2023;10(3):61–68. 10.15586/jkcvhl.v10i3.266

8. Lin J, Tang Z, Zhang C, Dong W, Liu Y, Huang H, et al. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma. Heliyon. 2023;9(5):e16076. 10.1016/j.heliyon.2023.e16076